

## Evaluating the “Recomline Toxoplasma IgM” Kit for Differentiating Toxoplasmic and Natural IgM

Imen Khammari<sup>1,2\*</sup>, Nada Ben Halima<sup>1,2</sup>, Samar Ismaïl<sup>1,2</sup>, Hamed Chouaieb<sup>1,2</sup>, Akila Fathallah<sup>1,2</sup>

<sup>1</sup>Department of Parasitology-Mycology, Faculty of Medicine of Sousse, The University of Sousse, Sousse, Tunisia.

<sup>2</sup>Laboratory of Parasitology-Mycology, Farhat Hached University Hospital Sousse, Tunisia.

\*E-mail ✉ [imenkhammari@yahoo.fr](mailto:imenkhammari@yahoo.fr)

Received: 24 April 2021; Revised: 02 August 2021; Accepted: 04 August 2021

### ABSTRACT

Serology is mostly used to diagnose toxoplasmosis by methodically looking for anti-toxoplasmic IgG and IgM. The difference between anti-*Toxoplasma* IgM and non-specific IgM, referred to as “natural,” is one of the challenges in interpreting *Toxoplasma* serology in pregnant women. This study aimed to assess the diagnostic efficacy of the “recomLine *Toxoplasma* IgM” immunoblot assay (Mikrogen, Diagnostik) in differentiating between normal IgM and specific anti-*Toxoplasma* IgM. Tests have been performed on 58 pregnant women's sera. ELISA-IgM was positive for all of these sera, while ELISA-IgG and IFI-IgG were negative. These sera are separated into two categories: Group 1: 30 sera were found to have natural IgM following three-week inspections for a maximum of three months. 28 sera with particular anti-toxoplasmic IgM were in group 2. The recomLine *Toxoplasma* IgM assay was used by the immunoblot kit to test the 28 sera. The eight recombinant toxoplasmic antigens that this test is based on are ROP1c, MIC3, GRA7, GRA8, p30, MAG1, GRA1, and rSAG1. Of the 28 confirmed IgM-specific sera, 11 had a sensitivity of 39.3% [22.1-59.3] in recomLine *Toxoplasma* IgM, while 28 of the 30 confirmed natural IgM sera had a specificity of 93.33% [76.5-98.8]. When IgM is positive and IgG is negative, the recomLine *Toxoplasma* IgM test can be recommended. The test's positive result increases the likelihood of a *Toxoplasma* seroconversion diagnosis, while its negative result does not rule it out. The test's positive predictive value was 84.6% [53.7-97.3] and its negative predictive value was 62.2% [46.5-75.8].

**Keywords:** Toxoplasmosis, Diagnosis, IgM natural, RecomLine *Toxoplasma* IgM, Specific IgM, Pregnant women

**How to Cite This Article:** Khammari I, Ben Halima N, Ismaïl S, Chouaieb H, Fathallah A. Evaluating the “Recomline Toxoplasma IgM” Kit for Differentiating Toxoplasmic and Natural IgM. Interdiscip Res Med Sci Spec. 2021;1(2):1-7. <https://doi.org/10.51847/G9XOXGb3WT>

### Introduction

*Toxoplasma gondii* (*T. gondii*) is an obligatory intracellular protozoan that causes the common parasitosis known as toxoplasmosis. In immune-competent people, it is harmless. However, because of the possibility of congenital toxoplasmosis through fetal infection, it becomes dangerous in immunocompromised people and pregnant women [1]. The primary method of diagnosing toxoplasmosis is serology, which involves methodically looking for anti-toxoplasmic IgG and IgM [1, 2]. The difference between anti-*Toxoplasma* IgM and non-specific IgM known as “natural” IgM is one of the challenges in interpreting *Toxoplasma* serology in pregnant women [3-5].

IgM is the first to show up in cases of *Toxoplasma* seroconversion. Nevertheless, the identification of IgM in the serum by itself is not a valid diagnostic standard for recent toxoplasmosis. In the first serum, the presence of IgM without IgG could indicate non-specific natural IgM detecting common antigens or toxoplasmic seroconversion in the early stages before the emergence of IgG [6-8].

To date, the sole recommendation for a serum with IgG negative and IgM positive was to continue the serology until IgG was detected. This is the only rationale that allows toxoplasmic seroconversion to be confirmed and the

specificity of IgM to be taken into consideration. The duration of this follow-up should be two to three months, which will postpone the diagnosis and, in turn, the therapeutic management [9].

There are numerous serodiagnostic kits on the market. Various antigenic preparations taken from tachyzoites are used in these kits. Overall, these tests' diagnostic capabilities are satisfactory. However, they occasionally raise the issue of non-standardization, necessitating the employment of other, more sensitive kits. Recently, serodiagnostic kits have been using recombinant antigens more and more [10].

This study aimed to assess the diagnostic efficacy of the “recomLine *Toxoplasma* IgM” immunoblot assay (Mikrogen, Diagnostik) in differentiating between normal IgM and specific anti-*Toxoplasma* IgM.

## Materials and Methods

### Material

A total of 58 sera from pregnant women referred to the Parasitology-Myecology laboratory for *Toxoplasma* serodiagnosis have been tested. All these sera were positive in ELISA-IgM (Platelia Toxo IgM®, BioRad) and negative in ELISA-IgG (Platelia Toxo IgG®, BioRad) and IFI-IgG (Toxo Spot IF®, BioMérieux) according to the suppliers' instructions.

These sera are divided into 2 groups:


*Group 1*: 30 sera with natural IgM confirmed after 3-week checkups for a period of up to 3 months.

*Group 2*: 28 sera with specific anti-toxoplasmic IgM.

### Methods

The 28 sera were tested by the immunoblot kit using the recomLine *Toxoplasma* IgM assay. This is a qualitative in vitro test for the detection of IgM versus *T. gondii* in human serum.

This test is based on 8 recombinant toxoplasmic antigens which are: ROP1c, MIC3, GRA7, GRA8, p30, MAG1, GRA1, and rSAG1. These antigens are fixed on nitrocellulose strips (**Figure 1**). The test is performed according to the manufacturer's recommendations. Interpretation of the profiles is performed according to the manufacturer's recommendations.



**Figure 1.** Nitrocellulose strip fixed with 8 recombinant *T. gondii* antigens with a reaction control and a conjugate control (IgG, IgA, and IgM).

For the evaluation of the test, scores were assigned to each antigen. The result is obtained by adding the corresponding scores of each strip. The positive, negative, and doubtful evaluation is indicated by the supplier (**Tables 1 and 2**).

**Table 1.** Evaluation of *T. gondii* antigen scores in the ‘*Toxoplasma* recomLine’.

Antigen	IgG Points	IgM Points	IgA Points
ROP1c	1	6	4
MIC3	0	2	4
GRA7	4	4	4
GRA8	4	4	4

P30	6	0	4
MAG1	2	1	2
GRA1	4	0	4
rSAG1	4	0	4

**Table 2.** Evaluation of test results in the *Toxoplasma* recomLine.

Score	Interpretation
$\leq 3$	Negative
4-5	Doubtful
$\geq 6$	Positive

## Results and Discussion

The results of the 58 sera tested in our work by the recomLine *Toxoplasma* IgM kit are shown in **Tables 3 and 4**.

**Table 3.** Results of sera with specific IgM obtained with recomLine *Toxoplasma* IgM.


N°	ROP1c	MIC3	GRA7	GRA8	P30	MAG1	GRA1	rSAG1	SCORE	Interpretation		
	6	2	4	4	0	1	0	0		Negative $\leq 3$	Doubtful 4-5	Positive $\geq 6$
1	6	0	4	4	0	0	0	0	14		Positive	
2	6	0	0	0	0	0	0	0	6		Positive	
3		0	4	4	0	0	0	0	8		Positive	
4	0	0	0	0	0	0	0	0	0		Negative	
5	0	0	0	0	0	0	0	0	0		Negative	
6	6	0	0	0	0	0	0	0	0		Positive	
7	0	0	0	0	0	0	0	0	0		Negative	
8	6	0	4	0	0	0	0	0	10		Positive	
9	6	0	0	4	0	0	0	0	10		Positive	
10	0	0	4	0	0	0	0	0	4		Negative	
11	0	0	0	0	0	0	0	0	0		Negative	
12	0	0	0	0	0	0	0	0	0		Negative	
13	0	0	0	0	0	0	0	0	0		Negative	
14	0	0	0	0	0	0	0	0	0		Negative	
15	0	0	0	4	0	0	0	0	4		Negative	
16	6	2	0	4	0	0	0	0	12		Positive	
17	6	0	0	4	0	0	0	0	10		Positive	
18	0	0	0	0	0	0	0	0	0		Negative	
19	0	0	0	0	0	0	0	0	0		Negative	
20	0	0	0	0	0	0	0	0	0		Negative	
21	6	0	0	0	0	0	0	0	6		Positive	
22	0	0	0	0	0	0	0	0	0		Negative	
23	0	0	0	0	0	0	0	0	0		Negative	
24	0	0	0	0	0	0	0	0	0		Negative	
25	6	0	0	0	0	0	0	0	6		Positive	
26	6	0	0	0	0	0	0	0	6		Positive	
27	0	0	4	0	0	0	0	0	4		Negative	
28	0	0	0	0	0	0	0	0	0		Negative	

**Table 4.** Results of sera with natural IgM obtained with recomLine *Toxoplasma* IgM.

Serum	ROP1c	MIC3	GRA7	GRA8	P30	MAG1	GRA1	rSAG1	SCORE	Interpretation
-------	-------	------	------	------	-----	------	------	-------	-------	----------------

N°	6	2	4	4	0	1	0	0		Negative ≤ 3	Doubtful 4-5	Positive ≥ 6
1	0	0	0	0	0	0	0	0	0		Negative	
2	0	0	0	0	0	0	0	0	0		Negative	
3	0	0	0	0	0	0	0	0	0		Negative	
4	0	0	0	0	0	0	0	0	0		Negative	
5	0	0	0	0	0	0	0	0	0		Negative	
6	0	0	0	0	0	0	0	0	0		Negative	
7	0	0	0	0	0	0	0	0	0		Negative	
8	0	0	0	0	0	0	0	0	0		Negative	
9	0	0	0	0	0	0	0	0	0		Negative	
10	0	0	0	0	0	0	0	0	0		Negative	
11	0	0	0	0	0	0	0	0	0		Negative	
12	0	0	0	0	0	0	0	0	0		Negative	
13	0	0	0	0	0	0	0	0	0		Negative	
14	0	0	0	0	0	0	0	0	0		Negative	
15	0	0	0	0	0	0	0	0	0		Negative	
16	6	0	0	4	0	0	0	0	10		Positive	
17	0	2	0	0	0	0	0	0	2		Negative	
18	0	0	0	0	0	0	0	0	0		Negative	
19	0	0	0	0	0	0	0	0	0		Negative	
20	0	2	0	0	0	0	0	0	2		Negative	
21	0	0	0	0	0	0	0	0	0		Negative	
22	0	0	0	0	0	0	0	0	0		Negative	
23	0	0	0	0	0	0	0	0	0		Negative	
24	0	0	0	0	0	0	0	0	0		Negative	
25	0	0	0	0	0	0	0	0	0		Negative	
26	0	0	4	4	0	0	0	0	14		Positive	
27	0	0	0	0	0	0	0	0	0		Negative	
28	0	0	0	0	0	0	0	0	0		Negative	
29	0	2	0	0	0	0	0	0	0		Negative	
30	0	2	0	0	0	0	0	0	0		Negative	

Among the 28 confirmed IgM-specific sera, 11 sera were positive in recomLine *Toxoplasma* IgM, that is, a sensitivity of 39.3% [22.1-59.3]. Among the 30 confirmed natural IgM sera, 28 sera were negative in recomLine *Toxoplasma* IgM, that is, a specificity of 93.33% [76.5-98.8]. Positive predictive value and negative predictive value were 84.6% [53.7-97.3] and 62.2% [46.5-75.8], respectively. **Figure 2** shows some examples of recomLine *Toxoplasma* IgM positive and negative profiles.



**Figure 2.** Examples of obtained profiles; strips 8-10 and 13: positive, strips 11-12 and 14: negative.

Although quantitative serological techniques are globally satisfactory in terms of sensitivity and specificity, they often pose the problem of discordance between results [11].

IgG testing allows the definition of the population at risk (non-immune patients). This research is conditioned by the quality of the IgG detection test [12].

Numerous comparative studies have been performed between the different commercialized serodiagnostic kits and have shown discrepancies between them. These discrepancies are mainly due to the lack of standardization and the differences between the used antigens [13].

Staging of infection is important for pregnant women since per gravid infection may result in congenital toxoplasmosis [14].

For these reasons, a seroconversion can only be considered when specific IgG appears, which occurs within a variable period depending on the used technique and the implementation of treatment [3].

Generally, a seroconversion can be excluded only after 3 serology tests showing the presence of IgM and the absence of IgG. This means that there is a considerable delay before concluding the non-specificity of IgM.

Indeed, if the result of the 2<sup>nd</sup> serum is identical to the 1<sup>st</sup>, the hypothesis of non-specific IgM tends to be confirmed. Therefore, performing 3 serology tests spaced one to two weeks apart is necessary to retain the hypothesis of natural IgM. And the woman will be considered seronegative vis-à-vis *Toxoplasma*.

One approach to improving serological diagnosis is to replace native antigens with recombinant antigens [10].

The advantages of recombinant antigens are the precise and known antigenic composition of the kit, the use of more than one antigen, the standardization, and the ease of the technique. These antigens are selected according to the acute or chronic phase and can be used for dating the infection [10]. Contrary to native antigens whose composition is generally not provided by the supplier, some antigens are characterized by a strong reactivity during the acute phase, others during the chronic phase, subsequently; the use of a single recombinant protein can identify the phase of the infection from a single serum which allows the dating of the infection and the study of avidity.

In recent years, several dozen genes encoding *T. gondii* proteins have been cloned. These antigens are mainly the surface antigens for example SAG1 (p30), SAG2 (P22), SAG3 (P43), and P35, the dense granule antigens for example GRA1 (P24), GRA2 (P28), GRA4, GRA5 (P32), GRA7 (P29) and the rhoptries antigens, for example, ROP1 (P66), ROP2 (P54), B10 (P41), MAG1, MIC1. These antigens have been used in their recombinant form to detect *T. gondii*-specific antibodies in serum [10, 15].

Recently commercialized, the “recomLine *Toxoplasma* IgM” immunoblot test is based on 8 recombinant antigens which are: ROP1c, MIC3, GRA7, GRA8, p30, MAG1, GRA1, and rSAG1. These antigens have been described in the literature as good markers of *Toxoplasma* infection. In our work, we applied this immunoblot assay for the discrimination between natural and specific IgM.

**ROP1:** this protein has a score of 6 in the “recomLine *Toxoplasma* IgM”. It alone may be sufficient to confirm the positivity of the test and therefore the specificity of IgM. The ROP1 protein is used as a good marker of recent infection. It has been detected in pregnant women with recent infections. However, this protein was weakly present in pregnant women with old infections [16, 17].

**MIC3:** this protein has a score of 2. Beghetto *et al.* [18] have shown that MIC3 protein can be used as a good marker of recent infection.

**GRA7:** is a good marker of recent infection according to Pfrepper *et al.* It has a score of 4 on the “recomLine *Toxoplasma* IgM”. Another study showed that GRA7 protein can be expressed during the different stages of *Toxoplasma* infection including tachyzoites and bradyzoites since dense granule proteins can be partially present at the membrane and cytoplasmic level and can be used to detect antibodies during the acute and chronic phase of the infection [15, 19, 20].

**GRA8:** this protein, which has the same score as GRA7, showed 100% avidity during the acute phase of infection according to the study by Sickinger *et al.* [21].

**P30:** It is the major surface protein of *T. gondii* and is expressed only in tachyzoites. P30 is the most immunogenic protein and plays an important role in host cell attachment, invasion, and modulation of the immune response. It represents 3 to 5% of total proteins. This protein is widely used in its purified, synthetic, or recombinant form in serological tests. Indeed, P30 is the first protein recognized by anti-toxoplasmic IgM and therefore constitutes a good marker of recent infection [22, 23].

*MAGI*: this protein is a marker of a recent infection. It was well present in 97.3% of patients with acute infections and only 7.5% of pregnant women with chronic infections. Therefore, this protein is also a good marker of acute infection [10].

*GRA1*: This dense granule protein is secreted by both tachyzoites and bradyzoites. The overall sensitivity of ELISA using the recombinant form of the protein in the detection of anti-*Toxoplasma* IgG ranges from 60-98% [24, 25]. It has been described as a good marker of the chronic phase of toxoplasmosis. For this reason, it is not incriminated in the detection of IgM by the recomLine *Toxoplasma* IgM test (score = zero). Ferrandiz *et al.* [25] reported a sensitivity of 78.2% in chronic infections versus 34% in acute infections.

*rSAG1*: the usefulness of this protein in the serodiagnosis of toxoplasmosis has been evaluated in numerous studies. It is very sensitive, especially in the detection of IgG [26].

According to our results, among the 28 confirmed IgM-specific sera, 11 sera were positive for recomLine *Toxoplasma* IgM, i. e. a sensitivity of 39.28%. Among the 30 confirmed natural IgM sera, 28 sera were negative in recomLine *Toxoplasma* IgM, i. e. a specificity of 93.33%.

## Conclusion

In conclusion, the recomLine *Toxoplasma* IgM test can be recommended in situations where IgM is positive and IgG is negative. The positivity of this test makes the diagnosis of *Toxoplasma* seroconversion very likely. However, its negativity does not rule out the diagnosis.

**Acknowledgments:** None

**Conflict of Interest:** None

**Financial Support:** None

**Ethics Statement:** This research was approved by Republique Tunisiennt Ministère De La Santé Hopital Universitaire Farhat Hached – Sousse.

## References

1. Robert-Gangneux F, Dardé ML. Epidemiology of and diagnostic strategies for Toxoplasmosis. Clin Microbiol Rev. 2012;25(2):264-96.
2. Khammari I, Saghrouni F, Yaacoub A, Meksi SG, Ach H, Garma L, et al. IgG western blot for confirmatory diagnosis of equivocal cases of Toxoplasmosis by EIA-IgG and fluorescent antibody test. Korean J Parasitol. 2013;51(4):485-8.
3. Flori P, Chene G, Varlet MN, Sung RT. Toxoplasma gondii serology in pregnant woman: characteristics and pitfalls. Ann Biol Clin. 2009;67(2):125-33.
4. Sun XM, Ji YS, Elashram SA, Lu ZM, Liu XY, Suo X, et al. Identification of antigenic proteins of Toxoplasma gondii RH strain recognized by human immunoglobulin G using immunoproteomics. J Proteomics. 2012;77:423-32.
5. Hruzik A, Asif AR, Gross U. Identification of Toxoplasma gondii SUB1 antigen as a marker for acute infection by use of an innovative evaluation method. J Clin Microbiol. 2011;49(7):2419-25.
6. Konishi E. Naturally occurring immunoglobulin M antibodies to Toxoplasma gondii in Japanese populations. Parasitology. 1991;102(2):157-62.
7. Garry DJ, Elimian A, Wiencek V, Baker DA. Commercial laboratory IgM testing for Toxoplasma gondii in pregnancy: a 20-year experience. Infect Dis Obstet Gynecol. 2005;13(3):151-3.
8. Montoya JG, Remington JS. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2008;47(4):554-66.
9. Cimon B, Penn P, Brun S, Chabasse D. How to resolve the difficulties encountered in the serodiagnosis of Toxoplasmosis in pregnant women? Immuno-Anal Biol Spé. 2002;17(3):143-7.
10. Holec-Gąsior L. Toxoplasma gondii Recombinant antigens as tools for serodiagnosis of human Toxoplasmosis: current status of studies. Clin Vaccine Immunol. 2013;20(9):1343-51.

11. Petithory JC, Ambroise-Thomas P, De Loye J, Pelloux H, Goullier-Fleuret A, Milgram M, et al. Le sérodiagnostic de la toxoplasmose: étude comparative multicentrique d’une gamme étalon, par les différents tests actuels et avec expression des résultats en unités internationales. Groupe de travail toxoplasmose du contrôle national de qualité en parasitologie, Syndicat des fabricants de réactifs de laboratoire, Groupe de travail standardisation des tests sérologiques du Réseau européen de lutte contre la toxoplasmose congénitale. *Bull World Health Organ.* 1996;74(3):291-8.
12. Khammari I, Saghrouni F, Lakhal S, Bougmiza I, Bouratbine A, Ben Said M, et al. Identification of soluble and membrane antigenic markers of acquired Toxoplasmosis by immunoblot. *Parasite Immunol.* 2014;36(12):684-93.
13. Cimon B, Marty P, Morin O, Bessières MH, Marx-Chemla C, Gay-Andrieu F, et al. Specificity of low anti-Toxoplasma IgG titers with IMx and AxSYM Toxo IgG assays. *Diagn Microbiol Infect Dis.* 1998;32(1):65-7.
14. Couvreur J, Desmonts G, Thulliez P. Prophylaxis of congenital Toxoplasmosis. Effects of Spiramycin on placental infection. *J Antimicrob Chemother.* 1988;22(Supplement\_B):193-200.
15. Pfrepper KI, Enders G, Gohl M, Krczal D, Hlobil H, Wassenberg D, et al. Seroreactivity to and avidity for recombinant antigens in Toxoplasmosis. *Clin Diagn Lab Immunol.* 2005;12(8):977-82.
16. Ferra B, Holec-Gasior L, Kur J. A new Toxoplasma gondii chimeric antigen containing fragments of SAG2, GRA1, and ROP1 proteins-impact of immunodominant sequences size on its diagnostic usefulness. *Parasitol Res.* 2015;114(9):3291-9.
17. Holec-Gasior L, Drapała D, Lautenbach D, Kur J. Toxoplasma gondii: usefulness of ROP1 recombinant antigen in an immunoglobulin G avidity assay for diagnosis of acute Toxoplasmosis in humans. *Pol J Microbiol.* 2010;59(4):307-10.
18. Beghetto E, Buffolano W, Spadoni A, Del Pezzo M, Di Cristina M, Minenkova O, et al. Use of an immunoglobulin G avidity assay bases on recombinant antigens for diagnosis of primary Toxoplasma gondii infection during pregnancy. *J Clin Microbiol.* 2003;41(12):5414-8.
19. Neudeck A, Stachelhaus S, Nischik N, Striepen B, Reichmann G, Fischer HG. Expression variance, biochemical and immunological properties of Toxoplasma gondii dense granule protein GRA7. *Microbes Infect.* 2002;4(6):581-90.
20. Khammari I, Lakhal S, Westermann B, Benkahla A, Bouratbine A, Dorsselaer AV, et al. Characterization of soluble and membrane-bound proteins of Toxoplasma gondii as diagnostic markers of infection. *Bacteriol Parasitol.* 2015;6(4):1.
21. Sickinger E, Gay-Andrieu F, Jonas G, Schultess J, Stieler M, Smith D, et al. Performance characteristics of the new architect Toxo IgG and Toxo IgG avidity assay. *Diagn Microbiol Infect Dis.* 2008;62(3):235-44.
22. Decoster A, Gontier P, Dehecq E, Demory JL, Duhamel M. Detection of anti-Toxoplasma immunoglobulin a antibodies by platelia-toxo IgA directed against P30 and by IMx Toxo IgA for diagnosis of acquired and congenital Toxoplasmosis. *J Clin Microbio.* 1995;33(8):2206-8.
23. Kimbita EN, Xuan X, Huang X, Miyazawa T, Fukumoto S, Mishima M, et al. Diagnosis of Toxoplasma gondii infection in cats by enzyme-linked immunosorbent assay using recombinant SAG1. *Vet Parasitol.* 2001;102(1-2):35-44.
24. Cesbron-Delauw MF, Guy B, Torpier G, Pierce RJ, Lenzen G, Cesbron JY, et al. Molecular characterization of a 23-kilodalton major antigen secreted by Toxoplasma gondii. *Proc Natl Acad Sci.* 1989;86(19):7537-41.
25. Ferrandiz J, Mercier C, Wallon M, Picot S, Cesbron-Delauw MF, Peyron F. Limited value of assays using detection of immunoglobulin G antibodies to the two recombinant dense granule antigens, GRA1 and GRA6 Nt of Toxoplasma gondii, for distinguishing between acute and chronic infections in pregnant women. *Clin Diagn Lab Immunol.* 2004;11(6):1016-21.
26. Fong MY, Lau YL, Zulqarnain M. Characterization of secreted recombinant Toxoplasma gondii surface antigen 2 (SAG2) heterologously expressed by the yeast Pichia pastoris. *Biotechnol Lett.* 2008;30(4):611-8.